Acceleron’s Sotatercept achieved primary and secondary endpoints in PULSAR trial in pulmonary arterial hypertension

Acceleron’s Sotatercept achieved primary and secondary endpoints in PULSAR trial in pulmonary arterial hypertension. (Credit: Belova59 from Pixabay)